Urinary epidermal growth factor concentrations in various human malignancies

A.-L. Mattila¹, I. Saario², L. Viinikka¹, O. Ylikorkala³ & J. Perheentupa¹

¹Children’s Hospital; ²Second Department of Surgery; and ³Department of Obstetrics and Gynaecology, University of Helsinki, 00290 Helsinki, Finland.

Summary We determined the concentrations of immunoreactive epidermal growth factor in the urine (U-irEGF) of 97 adult patients with various malignancies, including carcinomas of the urinary bladder, kidney, stomach, colon, rectum, breast, endometrium, uterus cervix, ovary, vagina, prostate, pancreas and thyroid, liposarcoma and skin melanoma. The relative U-irEGF concentrations (ng m⁻¹ creatinine) were higher (P=0.002) for the whole series of female patients than for healthy controls matched for sex and age. Such difference did not appear for male patients. The only specific group with a statistically supranormal U-irEGF concentration (P=0.0005) comprised women with endometrial carcinoma of the uterus.

Epidermal growth factor (EGF) appears to be involved in the regulation of proliferation, differentiation and differentiated functions of a multitude of cell types (Gospodarowicz, 1981; Carpenter & Zendegui, 1986). In certain normal cells in vitro EGF elicits transformation-associated responses (Stoscheck et al., 1986). There is also a considerable body of evidence associating EGF receptor with oncogenesis. The EGF receptor is the product of the c-erb B proto-oncogene, which is closely related to the v-erb B (Downward et al., 1984). The receptor is present in enormous numbers on the cells of many human epidermoid and glial malignancies (Lin et al., 1984; Merlino et al., 1984; Libermann et al., 1984). Many malignant cells produce another EGF receptor agonist, transforming growth factor alpha (TGF-α) (Todaro et al., 1980; Roberts et al., 1980). TGF-α is excreted in urine by patients with various malignancies (Sherwin et al., 1983), but not by healthy subjects (Twardzik et al., 1985).

Uchihashi et al. (1983) and Kurobe et al. (1985) found urinary excretion of EGF to be higher in patients with cancer than in healthy persons. This has not been generally accepted. We have now measured urinary immunoreactive EGF (U-irEGF) levels in patients with a variety of malignancies before and after tumour removal.

Materials and methods

Subjects and samples

Spot urine samples were collected from 97 patients (49 men and 48 women, aged 28–88 years) with various malignancies before surgical removal (or any other treatment) of the tumour. In addition to those shown in Figure 1, six patients had carcinomas, 1 of the vagina, 2 of the pancreas, and 3 of the thyroid, and 1 patient had liposarcoma and 1 skin melanoma. The malignancies included both metastasized and in situ tumours. We also measured U-irEGF concentration in 24 patients daily during the first week after removal of the tumour, and in a further 7 patients on the sixth postoperative day. For comparison, urine samples were collected from age- and sex-matched healthy subjects (56 men and 62 women, aged 28–86 years).

Assay procedures

Human EGF, used both as standard and labelled tracer, and a rabbit antiserum against it (8C-217, 3129) were donated by AMGen (Thousand Oaks, California). U-irEGF was measured by a specific homologous radioimmunoassay (Mattila et al., 1985) and creatinine by the kinetic method of Jaffe (Lustgarten & Wenk, 1972).

Results

To eliminate the effect of variability in the rate of water excretion, U-irEGF concentrations were expressed in ng per mg creatinine, as previously established (Dailey et al., 1978; Mattila, 1986). These relative U-irEGF concentrations of the whole series of female cancer patients were higher (P=0.002) than those of healthy female controls. No such difference appeared for the male cancer patients (Figure 2). The only specific group with a mean U-irEGF concentration higher than in controls, SDS being +1.3 ± 0.3 (mean ± s.e.m.; P=0.0005, Figure 1), comprised women with endometrial carcinoma. In no other group did the size and spread of the tumour seem to influence U-irEGF concentration. In the women with endometrial carcinoma the relative U-irEGF concentration did not change significantly after tumour removal (29.3 ± 4.2 vs. 25.7 ± 3.5 ng mg⁻¹ creatinine, mean ± s.e.m.). Of the female patients with conditions other than endometrial carcinoma, we had a postoperative sample only from 6. The concentration did not change significantly in any other specific group. Patients with renal carcinoma were an exception; unilateral nephrectomy caused ~50% decrease in their relative U-irEGF concentrations.

Gel exclusion chromatography revealed no abnormality in the apparent molecular nature of the urinary irEGF in patients with endometrial carcinoma. Determined in 4
patients a mean of 95% of the immunoreactivity coeluted with the EGF standard. The rest consisted of high-molecular weight forms of ~20 and 70 kilodaltons.

**Discussion**

Urinary irEGF concentrations were statistically supranormal in female cancer patients in general, but as far as specific patient groups were concerned, only in women with endometrial carcinoma. In contrast, Uchihashi et al. (1983) found statistically supranormal urinary immunoreactive EGF excretion in patients with carcinomas of the lung, maxilla, oesophagus, stomach, thyroid, breast, and cervix, and in patients with leukaemia, malignant lymphoma and multiple myeloma. Likewise, Kurobe et al. (1985) found supranormal urinary EGF levels in patients with gastric carcinoma. Neither series included patients with endometrial carcinoma.

Urinary EGF originates mostly from the kidneys (Rall et al., 1985; Olsen et al., 1984; Mattila et al., 1986). Thus an increase in urinary EGF concentration could be due to stimulation of renal EGF production by some tumour-associated factor. Alternatively, the malignant tumour might produce irEGF, which is excreted via blood to urine. The fact that the U-irEGF decreased by ~50% after unilateral nephrectomy, is an expected consequence of its renal origin.

Since the relative U-irEGF concentrations in the patients with endometrial carcinoma did not decrease after removal of the tumour, it is unlikely that the cancer produced or stimulated the production of the excess of U-irEGF. This excess might rather be another result of some carcinogenic factor(s) affecting these patients. Development of endometrial carcinoma has been suggested to be associated with a preceding supranormal oestrogen production and/or relative progesterone deficiency (Gambrell, 1986). Female sex steroids do appear to regulate urinary irEGF excretion. In both human beings and mice, females excrete more irEGF than males (Uchihashi et al., 1982; Mattila, 1986; Perheentupa et al., 1985). Moreover, in mice oestrogen treatment increased and progesterone treatment decreased U-irEGF concentration (Tuomela et al., 1985).

The statistically supranormal U-irEGF in the whole series of female patients is most interesting, but we have no explanation for this. Evidently it is associated with the fact that 22 of the 27 patients with female-specific carcinoma had values above age- and sex-specific mean values of controls. Against this background the case of endometrial carcinoma is not unique. Perhaps it was by chance that, of the groups with female specific tumours, only this category reached statistical significance.

In conclusion, U-irEGF concentration was statistically supranormal in the whole series of female cancer patients, but in groups with specific malignancies only in patients with endometrial carcinoma. The mechanism of this supranormal excretion is unknown, but it may be hormonally mediated.

We thank Anne Vikman and Hilkka Salmi for skilful technical assistance and Jean Margaret Perttunen for revision of the language. Human EGF and its antisera were gifts from AMGen (Thousand Oaks, CA).

**References**

Carpenter, G. & Zendegui, J.G. (1986). Epidermal growth factor, its receptor, and related proteins. Exp. Cell Res., 164, 1.

Dailey, G.E., Kraus, J.W. & Orth, D.N. (1978). Homologous radioimmunoassay for human epidermal growth factor (urogastrone). J. Clin. Endocrinol. Metab., 46, 929.

Dixon, W.J. (1981). BMDP Statistical Software, University of California Press: Berkeley.

Downward, J., Yarden, Y., Mayes, E. & 6 others (1984). Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (Lond.), 307, 521.

Gambrell, R.D. Jr (1986). The role of hormones in the etiology and prevention of endometrial cancer. In Clinics in Obstetrics and Gynaecology. Endometrial Cancer, Creasman, W.T. (ed) vol. 13, p. 695. W.B. Saunders: Philadelphia.
GOSPODAROWICZ, D. (1981). Epidermal and nerve growth factors in mammalian development. *Ann. Rev. Physiol.*, **43**, 251.

KUROBE, M.; AONO, M.; MORIGA, M.; FURUKAWA, S. & HAYASHI, K. (1985). Assessment by a two-site enzyme immunoassay of human epidermal growth factor (urogastrone) in the urine of patients with various gastrointestinal diseases including malignant tumours. *Biochem. Int.*, **11**, 817.

LIBERMANN, T.A.; BARTAL, A.D.; YARDEN, Y.; SCHLESSINGER, J. & SORIQ, H. (1984). Expression of epidermal growth factor receptors in human brain tumors. *Cancer Res.*, **44**, 753.

LIN, C.R.; CHEN, W.S.; KRUIGER, W. & 6 others (1984). Expression cloning of human EGF receptor complimentary DNA: Gene amplification and three related messenger RNA products in A431 cells. *Science*, **224**, 843.

LUSTGARTEN, J.A. & WENK, R.E. (1972). Simple, rapid, kinetic method for serum creatinine measurement. * Clin. Chem.*, **18**, 1419.

MATTILA, A.-L.; PERHEENTUPA, J.; PESONEN, K. & VIINIKKA, L. (1985). Epidermal growth factor in human urine from birth to puberty. *J. Clin. Endocrinol. Metab.*, **61**, 997.

MATTILA, A.-L.; PASTERNACK, A.; VIINIKKA, L. & PERHEENTUPA, J. (1986). Subnormal concentrations of urinary epidermal growth factor in patients with kidney disease. *J. Clin. Endocrinol. Metab.*, **62**, 1180.

MATTILA, A.-L. (1986). Human urinary epidermal growth factor: Effects of age, sex and female endocrine status. *Life Sci.*, **39**, 1879.

MERLING, G.T.; Xu, Y.; ISHII, S. & 5 others (1984). Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. *Science*, **224**, 417.

OLSEN, P.S.; NEXO, E.; POULSEN, S.S.; HANSEN, H.F. & KIRKEGAARD, P. (1984). Renal origin of rat urinary epidermal growth factor. *Regul. Peptides*, **10**, 37.

PERHEENTUPA, J.; LAKSHMANAN, J. & FISHER, D.A. (1985). Urine and kidney epidermal growth factor: Ontogeny and sex difference in the mouse. *Pediat. Res.*, **19**, 428.

RALL, L.B.; SCOTT, J.; BELL, G.I. & 4 others (1985). Mouse prepro-epidermal growth factor synthesis by the kidney and other tissues. *Nature*, **313**, 228.

ROBERTS, A.B.; LAMB, L.C.; NEWTON, D.L.; SPORN, M.B.; de LARCO, J.E. & TODARO, G.J. (1980). Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. *Proc. Natl Acad. Sci. USA*, **77**, 3494.

SHERWIN, S.A.; TWARDZIK, D.R.; BOHN, W.H.; COCKLEY, K.D. & TODARO, G.J. (1983). High-molecular-weight transforming growth factor activity in the urine of patients with disseminated cancer. *Cancer Res.*, **43**, 403.

STOSCHECK, C.M. & KING, L.E. Jr (1986). Role of epidermal growth factor in carcinogenesis. *Cancer Res.*, **46**, 1030.

TODARO, G.J.; FRYLING, C. & de LARCO, J.E. (1980). Transforming growth factors produced by certain human tumor cells: Polypeptides that interact with epidermal growth factor receptors. *Proc. Natl Acad. Sci.*, **77**, 5258.

TUOMELA, T.; RAPOLA, J.; VIKARI, M.; VIINIKKA, L. & PERHEENTUPA, J. (1985). Effects of estradiol and progesterone on epidermal growth factor of mouse urine. *Acta Endocrinol.*, **77**, 105.

TWARDZIK, D.R. & SHERWIN, S.A. (1985). Transforming growth factor (TGF) activity in human urine: Synergism between TGF-beta1 and urogastrone. *J. Cell. Biochem.*, **28**, 289.

UCHIHASHI, M.; HIRATA, Y.; FUJITA, T. & MATSUKURA, S. (1982). Age-related decrease of urinary excretion of human epidermal growth factor (hEGF). *Life Sci.*, **31**, 679.

UCHIHASHI, M.; HIRATA, Y.; NAKAJIMA, H.; FUJITA, T. & MATSUKURA, S. (1983). Urinary excretion of human epidermal growth factor (hEGF) in patients with malignant tumors. *Horm. Metabol. Res.*, **15**, 261.